Pyrimidines (including Hydrogenated) (e.g., Cytosine, Etc.) Patents (Class 514/49)
-
Publication number: 20140294769Abstract: Provided herein are compounds, methods and pharmaceutical compositions for use in treatment of viral infections, including hepatitis C virus (HCV) infections, in hosts in need thereof. In certain embodiments, the compounds are 2?,4?-fluoro nucleosides according to Formula 1001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein Base, RA, and PD are as described herein. In certain embodiments, 2?,4?-fluoro nucleosides are provided which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human.Type: ApplicationFiled: April 1, 2014Publication date: October 2, 2014Inventors: Benjamin Alexander MAYES, Adel M. MOUSSA, Alistair James STEWART
-
Patent number: 8846110Abstract: The present invention relates to compositions for the treatment of cancerous tissues in warm-blooded animals containing one or two anticancer agents attached to polymeric carriers having monomer units derived from one or more of N-(2-carboxypropyl)methacrylamide (2-CPMA), N-(3-carboxypropyl)methacrylamide (3-CPMA), N-(2-aminopropyl)methacrylamide (2-APMA) and/or N-(3-aminopropyl)methacrylamide (3-APMA) are also included. Anticancer agents in compositions can be attached to said polymeric carrier by side-chains which can be susceptible to hydrolysis by lysosomal enzymes intracellularly. Compositions can also include a targeting ligand attached to the polymeric carrier, optionally through a second linker.Type: GrantFiled: October 13, 2010Date of Patent: September 30, 2014Assignee: Rexahn Pharmaceuticals, Inc.Inventors: Young B. Lee, Deog J. Kim, Chang H. Ahn
-
Patent number: 8846639Abstract: In certain embodiments, the present invention provides oligomeric compounds having favorable toxicity profiles and therapeutic indexes. Compounds of the present invention comprise bicyclic nucleosides. Certain such bicyclic nucleosides are pyrimidines that do not include a methyl group at the 5-carbon. Oligomeric compounds comprising such nucleosides are less toxic than compounds comprising bicyclic nucleosides that do include a methyl group at the 5-carbon. In certain embodiments, the present invention provides methods of preparing and using such compounds.Type: GrantFiled: April 3, 2009Date of Patent: September 30, 2014Assignee: Isis Pharmaceutical, Inc.Inventors: Eric E. Swayze, Andrew M. Siwkowski
-
Patent number: 8846637Abstract: Provided herein are 2?-amino and 2?-thio bicyclic nucleosides and oligomenc compounds prepared therefrom. The novel bicyclic nucleosides provided herein are expected to be useful for enhancing one or more properties of the oligomeric compounds they are incorporated into such as nuclease resistance.Type: GrantFiled: June 2, 2011Date of Patent: September 30, 2014Assignee: Isis Pharmaceuticals, Inc.Inventors: Punit P. Seth, Thazha P. Prakash, Eric E. Swayze
-
Patent number: 8846896Abstract: Disclosed herein are methods of preparing a phosphorothioate nucleotide analog, which are useful in treating diseases and/or conditions such as viral infections.Type: GrantFiled: March 11, 2013Date of Patent: September 30, 2014Inventors: Vladimir Serebryany, Jyanwei Liu, Leonid Beigelman, Young Chun Jung, Jamison Rose, Shereen Ibrahim, Cavan McKeon, Luigi Anzalone
-
Patent number: 8846636Abstract: The disclosure provides nucleotide analogues that comprise tetrahydrofuranyl or tetrahydrothienyl moieties with quaternary centers at the 3? position, the pharmaceutical formulations comprising the analogues, and methods of using the analogues and formulations for treating, preventing, and/or inhibiting diseases or conditions associated with cancers and viruses.Type: GrantFiled: March 18, 2009Date of Patent: September 30, 2014Assignee: LCB Pharma Inc.Inventor: Yvan Guindon
-
Publication number: 20140286902Abstract: A pharmaceutical combination comprising a platinum-containing anticancer agent, and an Hsp90 inhibitor according to the following formulae (I) & (Ia), a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables structural formulae are defined herein. Also provided is a method of treating a proliferative disorder such as cancer in a subject in need thereof, using the pharmaceutical combination described herein.Type: ApplicationFiled: November 1, 2012Publication date: September 25, 2014Inventor: David Proia
-
Patent number: 8841278Abstract: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.Type: GrantFiled: October 3, 2013Date of Patent: September 23, 2014Assignee: Gilead Pharmasset LLCInventors: Elizabeth M. Bacon, Eda Canales, Aesop Cho, Jeromy J. Cottell, Manoj C. Desai, Michael Graupe, Hongyan Guo, Randall L. Halcomb, Darryl Kato, Choung U. Kim, Thorsten A. Kirschberg, Evan S. Krygowski, Scott E. Lazerwith, John O. Link, Hongtao Liu, Qi Liu, Richard L. Mackman, Michael L. Mitchell, Jay P. Parrish, Hyung-Jung Pyun, Joseph H. Saugier, Scott D. Schroeder, Jianyu Sun, James G. Taylor, James D. Trenkle, Winston C. Tse, Randall W. Vivian, William J. Watkins, Lianhong Xu
-
Patent number: 8841277Abstract: The present disclosure provides methods for treating subjects having non-small cell lung cancer, wherein the methods comprise administering to the subject a cytidine analog, such as 5-azacytidine. Also provided are methods relating to identification and treatment of particular non-small cell lung cancer types sensitive to particular cytidine analogs.Type: GrantFiled: June 7, 2013Date of Patent: September 23, 2014Assignee: Celgene CorporationInventors: Aaron N. Nguyen, Kyle J. MacBeth
-
Publication number: 20140274938Abstract: The invention relates to a composition for use in the treatment or prevention of recognition dysfunction, and/or for improving recognition, in a (prodromal) Alzheimer's patient, in particular in a drug-naive (prodromal) Alzheimer's patient, more particularly in a subject with a mini-mental state examination of 20-30.Type: ApplicationFiled: October 30, 2012Publication date: September 18, 2014Applicant: N.V. NutriciaInventors: Martine Groenendijk, Anke Bongers
-
Publication number: 20140271547Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2?-cyano, azido or amino nucleosides according to Formula 1001 or 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein Base, W, R1 and R2 are as described herein.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Inventors: David DUKHAN, Christophe Claude PARSY, Gilles GOSSELIN, Jean-Francois GRIFFON, Guillaume BRANDT, Cyril B. DOUSSON
-
Publication number: 20140271814Abstract: The present invention is a method and compound for treating cancer and tumors. The invention treats cancer by encapsulating certain cancer fighting drugs in a liposome. Peptides attached to the compound then guide the compound towards its target. During its journey, DSPE-PEG is used to stabilize the compound, to allow more time in the blood stream before losing effectiveness.Type: ApplicationFiled: March 14, 2013Publication date: September 18, 2014Inventor: Shiva Andrali
-
Publication number: 20140271819Abstract: Polymorphic forms of onapristone and methods of making and using such polymorphic forms are provided. Crystalline polymorphic forms can be characterized by their X-ray powder diffraction patterns and other properties.Type: ApplicationFiled: March 11, 2014Publication date: September 18, 2014Inventor: STEFAN PRONIUK
-
Publication number: 20140256668Abstract: The present disclosure relates to compounds of formula (I-A) using the compounds wherein Ring A and the variables X, Y, R3a, R3b, R3c, R3d, R4, R5, R5?, and m are defined herein, to pharmaceutical compositions comprising the compounds, and methods of using the compounds.Type: ApplicationFiled: May 23, 2013Publication date: September 11, 2014Applicant: MILLENNIUM PHARMACEUTICALS, INC.Inventors: Stephen CRITCHLEY, Thomas G. Gant, Steven P. Langston, Edward J. Olhava, Stephane Peluso
-
Publication number: 20140255339Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: ApplicationFiled: March 4, 2014Publication date: September 11, 2014Applicants: Idenix Pharmaceuticals, Inc., Universite Montpellier II, Centre National de la Recherche ScientifiqueInventors: Jean-Pierre SOMMADOSSI, Gilles GOSSELIN, Claire PIERRA, Christian PERIGAUD, Suzanne PEYROTTES
-
Publication number: 20140248375Abstract: The present invention relates generally to new chemical combinations and methods for their use in the treatment of proliferative diseases and in particular cancer.Type: ApplicationFiled: May 16, 2014Publication date: September 4, 2014Applicant: BIONOMICS LIMITEDInventors: Gabriel Kremmidiotis, Annabell Leske, Tina Lavranos
-
Publication number: 20140248241Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3?-deoxy nucleoside compounds according to Formula 3001a or 3001b: or a pharmaceutically acceptable salts, solvates, stereoisomeric forms, tautomeric forms, or polymorphic forms thereof, wherein PD, Base1 and Base2 are as provided herein.Type: ApplicationFiled: March 3, 2014Publication date: September 4, 2014Inventors: Alistair James STEWART, Adel M. MOUSSA, Benjamin Alexander MAYES, Francois-Rene ALEXANDRE, Dominique SURLERAUX, Christophe Claude PARSY, Claire PIERRA, David DUKHAN, Gilles GOSSELIN
-
Publication number: 20140249100Abstract: Disclosed are methods for preventing metastasis of cancer cells. The disclosed compounds can be used to prevent the spread of tumor or other types of cancer cells.Type: ApplicationFiled: March 3, 2013Publication date: September 4, 2014Applicant: Aerpio Therapeutics Inc.Inventors: Robert Shalwitz Shalwitz, Kevin Gene Peters
-
Patent number: 8822493Abstract: The present invention relates to SNS-595 and methods of treating cancer using the same.Type: GrantFiled: March 11, 2013Date of Patent: September 2, 2014Assignee: Sunesis Pharmaceuticals, Inc.Inventors: Michelle Arkin, Jennifer Hyde, Duncan Walker, Jasmin Wright
-
Patent number: 8822430Abstract: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.Type: GrantFiled: July 31, 2013Date of Patent: September 2, 2014Assignee: Gilead Pharmasset LLCInventors: Elizabeth M. Bacon, Eda Canales, Aesop Cho, Jeromy J. Cottell, Manoj C. Desai, Michael Graupe, Hongyan Guo, Randall L. Halcomb, Darryl Kato, Choung U. Kim, Thorsten A. Kirschberg, Evan S. Krygowski, Scott E. Lazerwith, John O. Link, Hongtao Liu, Qi Liu, Richard L. Mackman, Michael L. Mitchell, Jay P. Parrish, Hyung-Jung Pyun, Joseph H. Saugier, Scott D. Schroeder, Jianyu Sun, James G. Taylor, James D. Trenkle, Winston C. Tse, Randall W. Vivian, William J. Watkins, Lianhong Xu
-
Patent number: 8822429Abstract: The present invention refers to citicoline and to compositions containing it for topic use in treating glaucoma and/or ocular hypertension.Type: GrantFiled: February 17, 2011Date of Patent: September 2, 2014Assignee: Omikron Italia S.r.l.Inventors: Cristiano Virno, Marco Malizia
-
Publication number: 20140242026Abstract: Disclosed are methods for preventing metastasis of cancer cells. The disclosed compounds can be used to prevent the spread of tumor or other types of cancer cells.Type: ApplicationFiled: May 8, 2014Publication date: August 28, 2014Inventors: Robert Shalwitz, Kevin Gene Peters
-
Patent number: 8815830Abstract: The invention provides a compound of formula (I), wherein R1-R6 and X have any of the values described, as well as pharmaceutical compositions comprising such compounds and therapeutic methods comprising the administration of such compounds.Type: GrantFiled: March 28, 2014Date of Patent: August 26, 2014Assignee: Regents of the University of MinnesotaInventor: Carston R. Wagner
-
5'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES
Publication number: 20140235567Abstract: The present invention relates to 5?-Substituted Nucleoside Derivatives of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein B, X, Y, Z, R1, R2, R3 and R3? are as defined herein. The present invention also relates to compositions comprising at least one 5?-Substituted Nucleoside Derivative, and methods of using the 5?-Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.Type: ApplicationFiled: July 10, 2012Publication date: August 21, 2014Inventors: Vishal A. Verma, Ashok Arasappan, F. George Njoroge, Vinay Girijavallabhan, Stephane L. Bogen, Qun Dang, David B. Olsen -
Publication number: 20140234295Abstract: Provided herein is a pharmaceutical composition comprising at least one isoflavonoid. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions.Type: ApplicationFiled: November 1, 2011Publication date: August 21, 2014Applicant: MARSHALL EDWARDS, INC.Inventors: George Jeoffreys, Alison Johnson, Andrew Heaton, Ofir Moreno
-
Publication number: 20140235563Abstract: Embodiments of the invention are to compounds, methods, and compositions for use in the treatment of viral infections. More specifically embodiments of the invention are 2?,4?-substituted nucleoside compounds useful for the treatment of viral infections, such as HIV, HCV, and HBV infections.Type: ApplicationFiled: April 30, 2014Publication date: August 21, 2014Applicants: Gilead Sciences, Inc., Gilead Pharmasset LLCInventors: Michael Joseph Sofia, Jinfa Du
-
PYRIMIDINE NUCLEOSIDES AND THEIR MONOPHOSPHATE PRODRUGS FOR TREATMENT OF VIRAL INFECTIONS AND CANCER
Publication number: 20140235566Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing cancer and viral infections, in particular, HIV, HCV, Norovirus, Saporovirus, cytomegalovirus (CMV), herpes viruses (HSV-1, HSV-2), Dengue virus, Yellow fever, or HBV in human patients or other animal hosts. The compounds are certain N4-hydroxycytidine nucleosides derivatives, modified monophosphate and phosphonates prodrugs analogs, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HIV-1, HIV-2, HCV, Norovirus, Saporovirus, cytomegalovirus (CMV), herpes viruses (HSV-1, HSV-2), Dengue virus, Yellow fever, and HBV.Type: ApplicationFiled: October 29, 2013Publication date: August 21, 2014Applicants: Emory University, RFS Pharma, LLCInventors: Franck Amblard, Steven J. Coats, Raymond F. Schinazi -
Publication number: 20140235568Abstract: The present invention relates to the field of medical technology, and in particular relates to a kind of gemcitabine amide derivative with a novel structure. The new compounds of the present invention are very active with regard to many tumour cells such as human lung cancer, colon cancer, breast cancer and liver cancer etc., and therefore can be used for preparing anti-tumour drugs. In addition, these compounds also have anti-viral activity. Also disclosed are a preparation method for the compounds, a pharmaceutical composition containing the compounds and the use thereof in preparing drugs against tumours and viruses etc.Type: ApplicationFiled: September 26, 2012Publication date: August 21, 2014Inventors: Yunlong Song, Zhiyu Shao
-
Patent number: 8809265Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).Type: GrantFiled: October 19, 2012Date of Patent: August 19, 2014Assignee: AbbVie Inc.Inventors: Barry M. Bernstein, Rajeev M. Menon, Amit Khatri, Sven Mensing, Sandeep Dutta, Daniel E. Cohen, Thomas J. Podsadecki, Scott C. Brun, Walid M. Awni, Emily O. Dumas, Cheri E. Klein
-
Publication number: 20140227282Abstract: The problem of the present invention is to provide a highly effective therapeutic drug for pancreatic cancer and/or biliary tract cancer. A therapeutic drug for pancreatic cancer and/or biliary tract cancer containing the following (1) and (2) as essential components: (1) at least one kind of branched-chain amino acid selected from the group consisting of isoleucine, leucine and valine, (2) gemcitabine or a salt thereof.Type: ApplicationFiled: April 17, 2014Publication date: August 14, 2014Applicants: AJINOMOTO CO., INC., NATIONAL UNIVERSITY CORPORATION KOCHI UNIVERSITYInventors: Shinobu NISHITANI, Kazuhiro HANAZAKI, Toshiji SAIBARA
-
Publication number: 20140227260Abstract: The present invention relates to new aminopyrimidine inhibitors of tyrosine kinase activity, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: April 21, 2014Publication date: August 14, 2014Applicant: Auspex Pharmaceuticals, Inc.Inventor: Chengzhi Zhang
-
Publication number: 20140227221Abstract: Erastin analogs are useful in treating various cancers, particularly multiple myeloma. Erastin analogs are also useful in treating cancers that are resistant to other anticancer agents.Type: ApplicationFiled: December 4, 2013Publication date: August 14, 2014Applicant: Prolexys Pharmaceuticals, Inc.Inventors: Paul B. Robbins, Sudhir R. Sahasrabudhe
-
Patent number: 8802240Abstract: Disclosed are methods of increasing the chemosensitivity of normal and/or chemoresistant tumor or cancer cells using thyroid hormone analogs and/or nanoparticulate or polymeric forms thereof. Also disclosed are methods of increasing radiosensitivity of normal and/or radioresistant tumor or cancer cells using thyroid hormone analogs and/or nanoparticulate or polymeric forms thereof.Type: GrantFiled: January 6, 2012Date of Patent: August 12, 2014Assignee: Nanopharmaceuticals LLCInventors: Paul J. Davis, Shaker A. Mousa
-
Publication number: 20140221304Abstract: The present invention relates to 5?-Substituted Nucleoside Analogs of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, Z, R1, R2, R3 and R3? are as defined herein. The present invention also relates to compositions comprising at least one 5?-Substituted Nucleoside Analog, and methods of using the 5?-Substituted Nucleoside Analogs for treating or preventing HCV infection in a patient.Type: ApplicationFiled: July 10, 2012Publication date: August 7, 2014Inventors: Vishal A. Verma, Ashok Arasappan, F. George Njoroge, Kevin X. Chen
-
Publication number: 20140220006Abstract: The present invention relates to methods of diagnosing lung cancer in a patient, as well as methods of monitoring the progression of lung cancer and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein.Type: ApplicationFiled: January 30, 2014Publication date: August 7, 2014Applicant: Meso Scale Technologies, LLCInventors: Anahit Aghvanyan, Eli N. Glezer, John Kenten, Sudeep Kumar, Galina Nikolenko, Martin Stengelin
-
Publication number: 20140221305Abstract: Provided herein are compounds used to inhibit the deamination enzyme responsible for the inactivation of therapeutic compounds, and methods of using them.Type: ApplicationFiled: November 14, 2013Publication date: August 7, 2014Applicant: Eisai Inc.Inventors: Sergei Belyakov, Bridget Duvall, Dana Ferraris, Gregory Hamilton, Mark Vaal
-
Publication number: 20140221301Abstract: A method of treating a cancer comprising administering to a subject in need thereof an effective amount of a glycylcycline, for example tigecycline in combination with a chemotherapeutic such as daunorubicin or cytarabine.Type: ApplicationFiled: July 13, 2012Publication date: August 7, 2014Inventors: Aaron D. Schimmer, Marko Skrtic
-
Publication number: 20140213540Abstract: 2? and/or 3? prodrugs of 1?, 2?, 3? or 4?-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.Type: ApplicationFiled: March 20, 2014Publication date: July 31, 2014Applicants: IDENIX PHARMACEUTICALS, INC., L'UNIVERSITE MONTPELLIER II, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITA DEGLI STUDI DI CAGLIARIInventors: Richard STORER, Gilles GOSSELIN, Jean-Pierre SOMMADOSSI, Paolo LACOLLA
-
Publication number: 20140212509Abstract: Inhibitors of poly(ADP-ribose)polymerase, ways to make them and methods of treating patients using them are disclosed.Type: ApplicationFiled: May 24, 2013Publication date: July 31, 2014Applicant: ABBVIE INC.Inventors: Virajkumar B. Gandhi, Vincent L. Giranda, Jianchun Gong, Thomas D. Penning, Gui-Dong Zhu
-
Patent number: 8791089Abstract: The invention provides a method for supporting operational activities in daily living by providing a combination of (a) long-chain polyunsaturated fatty acids, particularly DHA and/or EPA, and (b) nucleosides or nucleotides, particularly uridine or its equivalent. The operational activities comprise eating; walking; toileting; bathing; grooming; dressing; use of communication equipment; making conversations; keeping appointments; use of household appliances; cleaning dishes; preparation of meal or drink; writing; reading; independent housekeeping; transportation and shopping.Type: GrantFiled: January 18, 2013Date of Patent: July 29, 2014Assignee: N.V. NutriciaInventors: Martine Groenendijk, Mattheus Cornelis de Wilde, Robert Johan Joseph Hageman, Patrick Joseph Gerardus Hendrikus Kamphuis
-
Patent number: 8791081Abstract: A method of treating a neoplastic disease in a subject includes administering to neoplastic cells of the subject an MGMT inhibitor and at least one of an antimitotic agent or a DNA damaging agent.Type: GrantFiled: February 29, 2008Date of Patent: July 29, 2014Assignee: Case Western Reserve UniversityInventors: Lili Liu, Stanton Gerson
-
Publication number: 20140206635Abstract: A metal-salen complex compound, which exhibits excellent noninvasiveness and can be efficiently transferred to an affected site, a local anesthetic containing this metal-salen complex compound, and an antineoplastic drug containing this metal-salen complex compound are provided. Regarding the metal-salen complex compound, a metal atom part in each of two molecules of a metal-salen complex or a derivative of the metal-salen complex is dimerized via water, and the metal-salen complex compound is mixed with a base to produce an ointment.Type: ApplicationFiled: May 10, 2012Publication date: July 24, 2014Applicants: IHI CORPORATIONInventors: Yoshihiro Ishikawa, Haruki Eguchi
-
Publication number: 20140206640Abstract: The present invention relates to 2?-Azido Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, R1, R2 and R3 are as defined herein. The present invention also relates to compositions comprising at least one 2?-Azido Substituted Nucleoside Derivative, and methods of using the 2?-Azido Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.Type: ApplicationFiled: April 11, 2012Publication date: July 24, 2014Applicant: Merck Sharp & Dohme Corp.Inventors: Vinay Girijavallabhan, F. George Njoroge, Stephane Bogen, Frank Bennett, Vishal Verma, Ashok Arasappan, Kevin X. Chen, Ying Huang, Angela Kerekes, Latha Nair, Dimitri Pissarnitski, Qun Dang, Ian Davies, David B. Olsen, Andrew Stamford, Joseph P. Vacca
-
Publication number: 20140206639Abstract: The present invention provides pharmaceutical compositions comprising a dihydro base described herein (e.g., compound DHdC). The dihydro base may show multiple tautomerism and may increase mutation of an RNA and/or DNA of a virus or cancer cell. The dihydro base may be used to reduce DNA methylation (e.g., in a cancer cell). The present invention also provides kits including the inventive pharmaceutical compositions and methods of treating a viral infection (e.g., influenza, HIV infection, or hepatitis C) or cancer using the pharmaceutical compositions or kits.Type: ApplicationFiled: January 22, 2014Publication date: July 24, 2014Applicant: Massachusetts Institute of TechnologyInventors: John M. Essigmann, Deyu Li, Katherine J. Silvestre
-
Publication number: 20140205596Abstract: The invention relates to compounds and methods of treatment relating to nicotinic receptor antagonists. For example, the compounds and methods of treatment function block the activity of certain acetylcholine receptors and subtypes therein, and are useful treating diseases and conditions mediated by nicotinic receptor stimulation, e.g., small cell lung cancer.Type: ApplicationFiled: June 22, 2012Publication date: July 24, 2014Applicant: INTRA-CELLULAR THERAPIES, INC.Inventors: Peng Li, Youyi Peng, John Tomesch, Lawrence P. Wennogle, Qiang Zhang
-
Publication number: 20140206637Abstract: Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD an inhibitor of NMD and a nonsense suppressor, whereby degradation of NMD susceptible mRNA is decreased and translation termination at a misplaced nonsense codon is blocked.Type: ApplicationFiled: June 13, 2012Publication date: July 24, 2014Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Tsafi Pe'ery, Michael B. Mathews, Mainul Hoque, Hartmut M. Hanauske-Abel
-
Publication number: 20140205595Abstract: It is an object of the present invention that the novel nicotinic receptor antagonists disclosed herein may be used in a broad array of clinical or medicinal facets. For example, it is a contemplated use of the present invention that the novel nicotinic receptor antagonists be used to inhibit the growth cycle of non-small cell lung cancer cells. Without being bound by theory, it is an object of the present invention that the nicotinic receptor antagonists disclosed herein are believed to possess reversible binding properties. Moreover, the compounds of the present invention are selective for 0.7 nAChR. For example, the compounds of the present invention are not believed to bind to 0.4 (32 nAChR neuromuscular receptors. It is also contemplated that the nicotinic receptor antagonists of the present invention will be used as a counter measure to treat exposure, or potential exposure, to a wide array of potential neurotoxins.Type: ApplicationFiled: June 22, 2012Publication date: July 24, 2014Inventors: Youyi Peng, Lawrence P. Wennogle, Qing Zhang, John Tomesch
-
Publication number: 20140199404Abstract: The present invention provides methods and compositions for treating cancer by administering a) a composition comprising nanoparticles that comprise paclitaxel and an albumin and b) a nucleoside analog (e.g., gemcitabine) based upon levels of a nucleoside transporter (e.g., hENT1).Type: ApplicationFiled: March 11, 2013Publication date: July 17, 2014Applicant: ABRAXIS BIOSCIENCE, LLCInventor: Carla HEISE
-
Publication number: 20140199261Abstract: Inositol trisphosphate (ITPP) causes normalization of tumor vasculature and is a particularly effective cancer therapy when a second chemotherapeutic agent is administered following partial vascularization. ITPP also treats, alone or in combination, multi-drug resistant cancers. ITPP can also be used to reduce the amount of a second chemotherapeutic drug required for anticancer activity. In addition, ITPP enhances immune response and treats hyperproliferative disorders.Type: ApplicationFiled: July 25, 2013Publication date: July 17, 2014Applicants: Universite de Strasbourg, NormOxys, Inc.Inventors: Yves Claude Nicolau, Jean-Marie Lehn, Claudine Kieda
-
Publication number: 20140199265Abstract: The present disclosure relates to nutritional compositions comprising a neurologic component, wherein, the neurologic component may promote brain and nervous system development and further provide neurological protection and repair. The neurologic component may include phosphatidylethanolamine, sphingomyelin, cytidine diphosphate-choline, ceramide, uridine, at least one ganglioside, and mixtures thereof. The disclosure further relates to methods of promoting brain and nervous system health by providing said nutritional compositions to target subjects, which includes pediatric subjects.Type: ApplicationFiled: January 11, 2013Publication date: July 17, 2014Applicant: Mead Johnson Nutrition CompanyInventors: Chenzhong Kuang, Yan Xiao, Eduard Poels, Zeina Jouni, Dirk Hondmann